This is a dose ranging exploratory phase 1 pilot study to assess engraftment, safety, and
efficacy of CP101, an oral microbiome therapeutic, in participants with active
mild-to-moderate Ulcerative colitis. A total of 30 patients who meet eligibility criteria
will be randomized 1:1 to either a short or extended induction dosing with CP101. An
assessment of the microbiome will occur at baseline, Day 6, Week 4, Week 8, Week 12, Week 16,
and Week 24.